Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 56.52 percent increase over losses of $(0.23) per share from the same period last year.
Telsey Advisory Group Maintains Market Perform on Best Buy Co, Lowers Price Target to $81
Telsey Advisory Group analyst Joseph Feldman maintains Best Buy Co (NYSE:BBY) with a Market Perform and lowers the price target from $83 to $81.
